3451

Hoffman RM, Levy BT, Allison JE. Rising use of multitarget stool DNA testing for colorectal cancer. JAMA Netw Open. 2021;4(9):e2122328. https://pubmed.ncbi.nlm.nih.gov/34473264/

3452

Wang K, Ma W, Wu K, et al. Healthy lifestyle, endoscopic screening, and colorectal cancer incidence and mortality in the United States: a nationwide cohort study. PLoS Med. 2021;18(2):e1003522. https://pubmed.ncbi.nlm.nih.gov/33524029/

3453

Larsen IK, Grotmol T, Almendingen K, Hoff G. Impact of colorectal cancer screening on future lifestyle choices: a three-year randomized controlled trial. Clin Gastroenterol Hepatol. 2007;5(4):477–83. https://pubmed.ncbi.nlm.nih.gov/17363335/

3454

Hoff G, Thiis-Evensen E, Grotmol T, Sauar J, Vatn MH, Moen IE. Do undesirable effects of screening affect all-cause mortality in flexible sigmoidoscopy programmes? Experience from the Telemark Polyp Study 1983–1996. Eur J Cancer Prev. 2001;10(2):131–7. https://pubmed.ncbi.nlm.nih.gov/19483252/

3455

Berstad P, Løberg M, Larsen IK, et al. Long-term lifestyle changes after colorectal cancer screening: randomised controlled trial. Gut. 2015;64(8):1268–76. https://pubmed.ncbi.nlm.nih.gov/25183203/

3456

Wang K, Ma W, Wu K, et al. Healthy lifestyle, endoscopic screening, and colorectal cancer incidence and mortality in the United States: a nationwide cohort study. PLoS Med. 2021;18(2):e1003522. https://pubmed.ncbi.nlm.nih.gov/33524029/

3457

Platz EA, Willett WC, Colditz GA, Rimm EB, Spiegelman D, Giovannucci E. Proportion of colon cancer risk that might be preventable in a cohort of middle-aged US men. Cancer Causes Control. 2000;11(7):579–88. https://pubmed.ncbi.nlm.nih.gov/10977102/

3458

O’Keefe SJD, Li JV, Lahti L, et al. Fat, fiber and cancer risk in African Americans and rural Africans. Nat Commun. 2015;6:6342. https://pubmed.ncbi.nlm.nih.gov/25919227/

3459

O’Keefe SJD, Li JV, Lahti L, et al. Fat, fiber and cancer risk in African Americans and rural Africans. Nat Commun. 2015;6:6342. https://pubmed.ncbi.nlm.nih.gov/25919227/

3460

Weber C. Nutrition. Diet change alters microbiota and might affect cancer risk. Nat Rev Gastroenterol Hepatol. 2015;12(6):314. https://pubmed.ncbi.nlm.nih.gov/25963512/

3461

Zhao Y, Zhan J, Wang Y, Wang D. The relationship between plant-based diet and risk of digestive system cancers: a meta-analysis based on 3,059,009 subjects. Front Public Health. 2022;10. https://pubmed.ncbi.nlm.nih.gov/35719615/

3462

McCarty MF. Mortality from Western cancers rose dramatically among African-Americans during the 20th century: are dietary animal products to blame? Med Hypotheses. 2001;57(2):169–74. https://pubmed.ncbi.nlm.nih.gov/11461167/

3463

Milsom I, Gyhagen M. The prevalence of urinary incontinence. Climacteric. 2019;22(3):217–22. https://pubmed.ncbi.nlm.nih.gov/30572737/

3464

Wieland LS, Shrestha N, Lassi ZS, Panda S, Chiaramonte D, Skoetz N. Yoga for treating urinary incontinence in women. Cochrane Database Syst Rev. 2019;2:CD012668. https://pubmed.ncbi.nlm.nih.gov/30816997/

3465

Pearlman A, Kreder K. Evaluation and treatment of urinary incontinence in the aging male. Postgrad Med. 2020;132(sup4):9–17. https://pubmed.ncbi.nlm.nih.gov/33017202/

3466

Faleiro DJA, Menezes EC, Capeletto E, Fank F, Porto RM, Mazo GZ. Association of physical activity with urinary incontinence in older women: a systematic review. J Aging Phys Act. 2019;27(4):906–13. https://pubmed.ncbi.nlm.nih.gov/30859902/

3467

Specht JKP. 9 myths of incontinence in older adults: both clinicians and the over-65 set need to know more. Am J Nurs. 2005;105(6):58–68. https://pubmed.ncbi.nlm.nih.gov/15930873/

3468

Muller N. Myths about incontinence in aging adults. Ostomy Wound Manage. 2009;55(5):22. https://pubmed.ncbi.nlm.nih.gov/20560204/

3469

Milsom I, Gyhagen M. The prevalence of urinary incontinence. Climacteric. 2019;22(3):217–22. https://pubmed.ncbi.nlm.nih.gov/30572737/

3470

Specht JKP. 9 myths of incontinence in older adults: both clinicians and the over-65 set need to know more. Am J Nurs. 2005;105(6):58–68. https://pubmed.ncbi.nlm.nih.gov/15930873/

3471

Pizzol D, Demurtas J, Celotto S, et al. Urinary incontinence and quality of life: a systematic review and meta-analysis. Aging Clin Exp Res. 2021;33(1):25–35. https://pubmed.ncbi.nlm.nih.gov/32964401/

3472

Milsom I, Gyhagen M. The prevalence of urinary incontinence. Climacteric. 2019;22(3):217–22. https://pubmed.ncbi.nlm.nih.gov/30572737/

3473

Ashton-Miller JA, DeLancey JOL. Functional anatomy of the female pelvic floor. Ann N Y Acad Sci. 2007;1101:266–96. https://pubmed.ncbi.nlm.nih.gov/17416924/

3474

Kuh D, Cardozo L, Hardy R. Urinary incontinence in middle aged women: childhood enuresis and other lifetime risk factors in a British prospective cohort. J Epidemiol Community Health. 1999;53(8):453–8. https://pubmed.ncbi.nlm.nih.gov/10562862/

3475

Danforth KN, Townsend MK, Lifford K, Curhan GC, Resnick NM, Grodstein F. Risk factors for urinary incontinence among middle-aged women. Am J Obstet Gynecol. 2006;194(2):339–45. https://pubmed.ncbi.nlm.nih.gov/16458626/

3476

Robinson D, Giarenis I, Cardozo L. You are what you eat: the impact of diet on overactive bladder and lower urinary tract symptoms. Maturitas. 2014;79(1):8–13. https://pubmed.ncbi.nlm.nih.gov/25033724/

3477

Imamura M, Williams K, Wells M, McGrother C. Lifestyle interventions for the treatment of urinary incontinence in adults. Cochrane Database Syst Rev. 2015;(12):CD003505. https://pubmed.ncbi.nlm.nih.gov/26630349/

3478

Subak LL, Wing R, West DS, et al. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med. 2009;360(5):481–90. https://pubmed.ncbi.nlm.nih.gov/19179316/

3479

Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36. https://pubmed.ncbi.nlm.nih.gov/12811491/

3480

Flore K, Fauber J, Wynn M. Drug firms helped create $3 billion overactive bladder market. Milwaukee Journal Sentinel. https://www.jsonline.com/story/news/investigations/2016/10/16/overactive-bladder-drug-companies-helped-create-3-billion-market/92030360/. Published October 15, 2016. Accessed August 24, 2022.; https://www.jsonline.com/story/news/investigations/2016/10/16/overactive-bladder-drug-companies-helped-create-3-billion-market/92030360/

3481

Mitcheson HD, Samanta S, Muldowney K, et al. Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial. Eur Urol. 2019;75(2):274–82. https://pubmed.ncbi.nlm.nih.gov/30661513/

3482

Cho A, Eidelberg A, Butler DJ, et al. Efficacy of daily intake of dried cranberry 500 mg in women with overactive bladder: a randomized, double-blind, placebo controlled study. J Urol. 2021;205(2):507–13. https://pubmed.ncbi.nlm.nih.gov/32945735/